Crispr Therapeutics AG (NASDAQ:CRSP) has earned a consensus recommendation of “Buy” from the sixteen analysts that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, four have issued a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $62.47.
Several research firms have recently weighed in on CRSP. Wells Fargo & Co began coverage on shares of Crispr Therapeutics in a research report on Wednesday. They set an “outperform” rating and a $65.00 price objective on the stock. Guggenheim initiated coverage on shares of Crispr Therapeutics in a research report on Tuesday. They set a “neutral” rating on the stock. Zacks Investment Research upgraded shares of Crispr Therapeutics from a “hold” rating to a “strong-buy” rating and set a $42.00 target price on the stock in a research report on Tuesday. BidaskClub cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, October 5th. Finally, Raymond James initiated coverage on shares of Crispr Therapeutics in a research report on Thursday, September 20th. They issued an “underperform” rating on the stock.
Large investors have recently modified their holdings of the stock. Rockefeller Capital Management L.P. purchased a new position in Crispr Therapeutics in the 2nd quarter worth $116,000. Signaturefd LLC raised its position in Crispr Therapeutics by 123.8% in the 2nd quarter. Signaturefd LLC now owns 2,350 shares of the company’s stock worth $138,000 after purchasing an additional 1,300 shares during the period. First Mercantile Trust Co. purchased a new position in Crispr Therapeutics in the 2nd quarter worth $141,000. SeaCrest Wealth Management LLC increased its position in shares of Crispr Therapeutics by 202.9% in the second quarter. SeaCrest Wealth Management LLC now owns 2,726 shares of the company’s stock valued at $160,000 after acquiring an additional 1,826 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Crispr Therapeutics by 66.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,827 shares of the company’s stock valued at $166,000 after acquiring an additional 1,127 shares during the period. Institutional investors own 39.13% of the company’s stock.
Shares of Crispr Therapeutics stock traded up $0.75 on Friday, hitting $37.70. 1,644,820 shares of the company traded hands, compared to its average volume of 1,240,602. The stock has a market cap of $2.09 billion, a P/E ratio of -22.05 and a beta of 3.70. Crispr Therapeutics has a 12-month low of $16.51 and a 12-month high of $73.90.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Wednesday, August 8th. The company reported ($0.82) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by ($0.19). The company had revenue of $1.09 million for the quarter, compared to analysts’ expectations of $1.47 million. Crispr Therapeutics had a negative net margin of 245.57% and a negative return on equity of 39.58%. On average, equities research analysts forecast that Crispr Therapeutics will post -2.92 EPS for the current year.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Further Reading: What is a put option?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.